Clinical Trial Update: Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the feasibility and tolerability of talimogene laherparepvec (IMLYGIC) for treating cutaneous neurofibromas in adults with Neurofibroma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type

Drugs mentioned

• Imlygic (Talimogene laherparepvec)

Snippet

Sponsor: Johns Hopkins University | Conditions: NF1, Neurofibromatosis | Phase 1 | Status: RECRUITING